• Outset Medical posted Q1 net loss of USD 19 million, narrowing from year-ago loss of USD 25.8 million, as revenue fell 6% to USD 27.9 million.
• Gross margin widened 6.2 percentage points to 43.4%, with product gross margin rising to 52.4% and service and other gross margin climbing to 25.5%.
• Recurring revenue from Tablo consumables and services was USD 22.5 million, roughly flat year over year, while cash used during quarter was USD 12 million, leaving total cash of USD 161 million at quarter-end.
• CEO Leslie Trigg cited progress toward profitability on record gross margin performance, with utilization strong and service margins expanding.
• Outlook reiterated for 2026 revenue of USD 125 million to USD 130 million, with non-GAAP gross margin expected in low-to-mid 40% range.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outset Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071602PRIMZONEFULLFEED9714583) on May 07, 2026, and is solely responsible for the information contained therein.